keyword
MENU ▼
Read by QxMD icon Read
search

hcv reinfection

keyword
https://www.readbyqxmd.com/read/29778265/a-guide-to-the-economics-of-hepatitis-c-virus-cure-in-2017
#1
REVIEW
Benjamin P Linas, Shayla Nolen
This commentary reviews the core principals of cost-effectiveness and applies them to the rapidly evolving context of hepatitis C virus treatment in the United States. The article provides a foundation of evidence that hepatitis C virus treatment provides good economic value, even though it is expensive, and even when treating people who inject drugs who are at high risk for hepatitis C virus reinfection. The price of medications has decreased, but the high price continues to limit access to care. This wedge between cost effectiveness and affordability stands front and center as one of the leading obstacles to elimination...
June 2018: Infectious Disease Clinics of North America
https://www.readbyqxmd.com/read/29778262/understanding-and-addressing-hepatitis-c-virus-reinfection-among-men-who-have-sex-with-men
#2
REVIEW
Thomas C S Martin, Andri Rauch, Luisa Salazar-Vizcaya, Natasha K Martin
Hepatitis C virus reinfection rates among men who have sex with men are high. Factors associated with infection point to varied sexual and drug-related risks that could be targeted for interventions to prevent infection/reinfection. Modeling indicates that tackling increasing incidence and high reinfection rates requires high levels of hepatitis C virus treatment combined with behavioral interventions. Enhanced testing strategies and prompt retreating of reinfection may be required to promptly diagnosed reinfections...
June 2018: Infectious Disease Clinics of North America
https://www.readbyqxmd.com/read/29778261/strategies-to-reduce-hepatitis-c-virus-reinfection-in-people-who-inject-drugs
#3
REVIEW
Marianne Martinello, Gregory J Dore, Gail V Matthews, Jason Grebely
Reinfection after direct-acting antiviral therapy may pose a challenge to hepatitis C virus elimination efforts. Reinfection risk is cited as a reason for not offering treatment to people who inject drugs. As treatment scale-up expands among populations with risks for reacquisition, acknowledgment that reinfection can and will occur is essential. Efforts to prevent and manage reinfection should be incorporated into individual- and population-level strategies. The risk of reinfection after successful treatment emphasises the need for education, harm reduction, and posttreatment surveillance...
June 2018: Infectious Disease Clinics of North America
https://www.readbyqxmd.com/read/29727295/croi-2018-highlights-of-viral-hepatitis
#4
Anne F Luetkemeyer, David L Wyles
At the 2018 Conference on Retroviruses and Opportunistic Infections (CROI), there was a major focus on hepatitis C virus (HCV) elimination and improving each component of the hepatitis C care cascade. Several countries and cohorts have demonstrated the remarkable impact that universal HCV testing and unrestricted access to hepatitis C treatment can have on markedly reducing incident HCV infections and HCV infection prevalence, including in people who inject drugs and HIV/HCV-coinfected populations. However, in many settings, substantial barriers to widespread HCV treatment remain, including undiagnosed HCV infection, particularly in populations outside the standard "baby boomer" birth cohort (ie, born 1945-1965); restricted access to hepatitis C treatment in those with known HCV infection; reinfection with HCV; and migration of HCV-infected populations...
May 2018: Topics in Antiviral Medicine
https://www.readbyqxmd.com/read/29722275/eliminating-hiv-hcv-co-infection-in-gay-and-bisexual-men-is-it-achievable-through-scaling-up-treatment
#5
Rachel Sacks-Davis, Alisa E Pedrana, Nick Scott, Joseph S Doyle, Margaret E Hellard
Broad availability of direct-acting antiviral therapy for hepatitis C virus (HCV) raises the possibility that HCV prevalence and incidence can be reduced through scaling-up treatment, leading to the elimination of HCV. High rates of linkage to HIV care among HIV-infected gay and bisexual men may facilitate high uptake of HCV treatment, possibly making HCV elimination more achievable in this group. Areas covered: This review covers HCV elimination in HIV-infected gay and bisexual men, including epidemiology, spontaneous clearance and long term sequelae in the absence of direct-acting antiviral therapy; direct-acting antiviral therapy uptake and effectiveness in this group; HCV reinfection following successful treatment; and areas for further research...
May 3, 2018: Expert Review of Anti-infective Therapy
https://www.readbyqxmd.com/read/29660224/shortened-therapy-of-eight-weeks-with-paritaprevir-ritonavir-ombitasvir-and-dasabuvir-is-highly-effective-in-people-with-recent-hcv-genotype-1-infection
#6
Marianne Martinello, Sanjay Bhagani, Edward Gane, Chloe Orkin, Graham Cooke, Gregory J Dore, Kathy Petoumenos, Tanya L Applegate, Elise Tu, Philippa Marks, Nicole Pagani, Jason Grebely, Mark Nelson, Gail V Matthews
Paritaprevir/ritonavir/ombitasvir and dasabuvir with or without ribavirin for 12 weeks is approved for treatment of chronic HCV genotype 1 infection. This study assessed the efficacy of shortened duration paritaprevir/ritonavir/ombitasvir and dasabuvir with or without ribavirin for eight weeks among people with recent HCV infection. In this open-label single-arm trial conducted in Australia, England and New Zealand, adults with recent HCV (duration of infection <12 months) received paritaprevir/ritonavir/ombitasvir and dasabuvir (with weight-based ribavirin for genotype 1a and 1, no subtype) for eight weeks...
April 16, 2018: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/29660211/effectiveness-and-cost-effectiveness-of-interventions-targeting-harm-reduction-and-chronic-hepatitis-c-cascade-of-care-in-people-who-inject-drugs-the-case-of-france
#7
Anthony Cousien, Viet Chi Tran, Sylvie Deuffic-Burban, Marie Jauffret-Roustide, Guillaume Mabileau, Jean-Stéphane Dhersin, Yazdan Yazdanpanah
Direct-acting antivirals (DAAs) represent an opportunity to improve hepatitis C virus (HCV) care cascade. This, combined with improved harm reduction interventions may lead to HCV elimination especially in people who inject drugs (PWID). We assessed the effectiveness/cost-effectiveness of improvements in harm reduction and chronic hepatitis C (CHC) care cascade in PWID in France. We used a dynamic model of HCV transmission and CHC natural history and evaluated: improved needle/syringe programs-opioid substitution therapies, faster diagnosis/linkage to care, earlier treatment initiation, alone and in combination among active PWID (mean age=36)...
April 16, 2018: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/29599610/successful-combination-of-direct-antiviral-agents-in-liver-transplanted-patients-with-recurrent-hepatitis-c-virus
#8
Christian Rupp, Theresa Hippchen, Manuel Neuberger, Peter Sauer, Jan Pfeiffenberger, Wolfgang Stremmel, Daniel Nils Gotthardt, Arianeb Mehrabi, Karl-Heinz Weiss
AIM: To analyze the safety and efficiency of direct-acting antiviral (DAA) regimens in liver-transplanted patients with hepatitis C virus (HCV) reinfection. METHODS: Between January 2014 and December 2016, 39 patients with HCV reinfection after liver transplantation were treated at our tertiary referral center with sofosbuvir (SOF)-based regimens, including various combinations with interferon (IFN), daclatasvir (DAC), simeprivir (SIM) and/or ledipasvir (LDV). Thirteen patients were treated with SOF + IFN ± RBV...
March 28, 2018: World Journal of Gastroenterology: WJG
https://www.readbyqxmd.com/read/29573533/rapid-decline-of-anti-hepatitis-c-virus-hcv-antibodies-following-early-treatment-of-incident-hcv-infections-in-hiv-infected-men-who-have-sex-with-men
#9
K Aebi-Popp, G Wandeler, L Salazar-Vizcaya, K Metzner, M Stöckle, M Cavassini, M Hoffmann, A Lüthi, F Suter, E Bernasconi, J Fehr, H Furrer, A Rauch
OBJECTIVES: Following clearance of incident hepatitis C virus (HCV) infections, HCV antibody levels may decline, resulting in seroreversion. It is unclear to what extent HCV antibody level trajectories differ between patients with treatment-induced sustained virological response (SVR), those with spontaneous clearance and those with untreated replicating HCV infection. We investigated HCV antibody level dynamics in HIV-infected MSM with different clinical outcomes. METHODS: We investigated anti-HCV antibody level dynamics following an incident HCV infection in 67 HIV-infected men who have sex with men (MSM) with different clinical outcomes: SVR (n = 33), spontaneous clearance (n = 12), and untreated replicating infection (n = 22)...
March 24, 2018: HIV Medicine
https://www.readbyqxmd.com/read/29552922/-three-decades-of-the-hepatitis-c-virus-from-the-discovery-to-the-potential-global-elimination-the-success-of-translational-researches
#10
Alajos Pár, Gabriella Pár
More than 25 years after the discovery of hepatitis C virus, the development of the direct acting antivirals can lead to the regional or long-term global elimination of the virus with over 90% efficacy. This is the success of basic and clinical translational research. Yet, some unsolved challanges remain, such as the great number of unidentified patients who are not aware of their condition, the limited access to the therapy due to the high prices of the drugs, and the treatment of resistance-associated variants...
March 2018: Orvosi Hetilap
https://www.readbyqxmd.com/read/29510685/case-report-8-years-after-liver-transplantation-de-novo-hepatocellular-carcinoma-8-months-after-hcv-clearance-through-ifn-free-antiviral-therapy
#11
Giuliano Ramadori, Patrizia Bosio, Federico Moriconi, Ihtzaz A Malik
BACKGROUND: After orthotopic liver transplantation (OLT) for hepatocellular carcinoma (HCC), recurrent HCC mostly develops within 2 years. All cases of de novo HCC described so far occurred later than 2 years after OLT. Prevention of post-transplantation HCC has usually been tried to achieve by curing or controlling recurrent liver disease. This has been rationale for treatment with interferon (IFN)/ribavirin of HCV-recurrence in patients after OLT, transplanted for advanced HCV-induced liver disease and/or HCC...
March 6, 2018: BMC Cancer
https://www.readbyqxmd.com/read/29477639/critical-challenges-and-emerging-opportunities-in-hepatitis-c-virus-research-in-an-era-of-potent-antiviral-therapy-considerations-for-scientists-and-funding-agencies
#12
REVIEW
Ralf Bartenschlager, Thomas F Baumert, Jens Bukh, Michael Houghton, Stanley M Lemon, Brett D Lindenbach, Volker Lohmann, Darius Moradpour, Thomas Pietschmann, Charles M Rice, Robert Thimme, Takaji Wakita
The development and clinical implementation of direct-acting antivirals (DAAs) has revolutionized the treatment of chronic hepatitis C. Infection with any hepatitis C virus (HCV) genotype can now be eliminated in more than 95% of patients with short courses of all-oral, well-tolerated drugs, even in those with advanced liver disease and liver transplant recipients. DAAs have proven so successful that some now consider HCV amenable to eradication, and continued research on the virus of little remaining medical relevance...
March 15, 2018: Virus Research
https://www.readbyqxmd.com/read/29438195/incidence-of-new-hepatitis-c-virus-infection-is-still-increasing-in-french-msm-living-with-hiv
#13
Pierre Pradat, Thomas Huleux, François Raffi, Pierre Delobel, Marc-Antoine Valantin, Isabelle Poizot-Martin, Pascal Pugliese, Jacques Reynes, David Rey, Bruno Hoen, André Cabie, Firouzé Bani-Sadr, Antoine Cheret, Claudine Duvivier, Christine Jacomet, Anne Fresard, Laurent Hustache-Mathieu, Laurent Cotte
OBJECTIVE: High hepatitis C virus (HCV) treatment uptake combined with effective direct-acting antiviral-based regimens resulted in a dramatic decline of HCV infection in French people living with HIV (PLWH). We assessed the yearly incidence of new HCV infection in PLWH enrolled in the large French Dat'AIDS cohort from 2012 to 2016 with a specific focus on MSM. METHODS: The incidence of new HCV infection was determined yearly in HCV-negative PLWH with serological follow-up during 2012-2016...
May 15, 2018: AIDS
https://www.readbyqxmd.com/read/29427493/the-next-wave-of-hepatitis-c-virus-the-epidemic-of-intravenous-drug-use
#14
REVIEW
Mitchell L Shiffman
The epidemic of hepatitis C virus (HCV) began in the 1960s when transmission was primarily the result of blood transfusions. By 1990, when HCV was identified and a serologic test for screening donated blood was implemented, 123 million persons had already become infected worldwide and HCV was the most common cause of cirrhosis, hepatocellular carcinoma and the most common indication for liver transplantation. Approximately 75% of persons with HCV are "baby boomers" born between the years 1945 and 1965...
February 2018: Liver International: Official Journal of the International Association for the Study of the Liver
https://www.readbyqxmd.com/read/29407313/development-of-duodenal-ulcers-due-to-the-discontinuation-of-proton-pump-inhibitors-after-the-induction-of-sofosbuvir-plus-ledipasvir-therapy-a-report-of-two-cases
#15
S Miuma, H Miyaaki, Y Miyazoe, T Suehiro, R Sasaki, H Shibata, N Taura, K Nakao
Sofosbuvir plus ledipasvir (SOF-LDV) combination therapy is a promising therapy for post-transplant hepatitis C virus (HCV) reinfection. It is known that gastric pH elevation induces lower absorption of ledipasvir; therefore, the use of proton pump inhibitors (PPIs) should be considered regarding dose reduction after SOF-LDV therapy induction. Here, we report two patients who developed duodenal ulcers due to the discontinuation of PPIs after the induction of SOF-LDV therapy for post-transplant HCV reinfection...
January 2018: Transplantation Proceedings
https://www.readbyqxmd.com/read/29369303/report-from-the-international-conference-on-viral-hepatitis-2017
#16
Vicente Soriano, Benjamin Young, Nancy Reau
The International Conference on Viral Hepatitis 2017 brought exciting news on the treatment of viral hepatitis. The most recent estimates of the burden for hepatitis B virus and hepatitis C virus (HCV) infections were presented. The current gaps and prospects for regional and global eradication of viral hepatitis were discussed on the light of the WHO roadmap until 2030. Debates focused on hepatitis C and expectations using the new approved HCV pan-genotypic, once daily, oral direct-acting antivirals (DAAs), glecaprevir-pibrentasvir, and sofosbuvir-velpatasvir-voxilaprevir...
January 2018: AIDS Reviews
https://www.readbyqxmd.com/read/29316030/understanding-and-addressing-hepatitis-c-reinfection-in-the-oral-direct-acting-antiviral-era
#17
REVIEW
O Falade-Nwulia, M S Sulkowski, A Merkow, C Latkin, S H Mehta
The availability of effective, simple, well-tolerated oral direct-acting antiviral (DAA) hepatitis C regimens has raised optimism for hepatitis C virus (HCV) elimination at the population level. HCV reinfection in key populations such as people who inject drugs (PWID) and HIV-infected men who have sex with men (MSM) however threatens the achievement of this goal from a patient, provider and population perspective. The goal of this review was to synthesize our current understanding of estimated rates and factors associated with HCV reinfection...
March 2018: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/29316001/directly-observed-therapy-of-chronic-hepatitis-c-with-ledipasvir-sofosbuvir-in-people-who-inject-drugs-at-risk-of-nonadherence-to-direct-acting-antivirals
#18
A Schütz, S Moser, C Schwanke, R Schubert, J Luhn, E Gutic, T Lang, M Schleicher, H Haltmayer, M Gschwantler
An important subgroup of people who inject drugs (PWID) receiving opioid agonist therapy (OAT) cannot be treated in the setting of a hepatology centre and would not regularly ingest their medication when handed to them for self-administration. Our hypothesis was that chronic hepatitis C in these patients could be ideally managed if modern, interferon-free regimens were administered together with OAT under direct observation of a physician or nurse at a low-threshold facility. In this open-label, noninterventional, proof-of-concept study (ClinicalTrials...
January 5, 2018: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/29310928/sofosbuvir-and-velpatasvir-for-hepatitis-c-virus-infection-in-people-with-recent-injection-drug-use-simplify-an-open-label-single-arm-phase-4-multicentre-trial
#19
Jason Grebely, Olav Dalgard, Brian Conway, Evan B Cunningham, Philip Bruggmann, Behzad Hajarizadeh, Janaki Amin, Julie Bruneau, Margaret Hellard, Alain H Litwin, Philippa Marks, Sophie Quiene, Sharmila Siriragavan, Tanya L Applegate, Tracy Swan, Jude Byrne, Melanie Lacalamita, Adrian Dunlop, Gail V Matthews, Jeff Powis, David Shaw, Maria Christine Thurnheer, Martin Weltman, Ian Kronborg, Curtis Cooper, Jordan J Feld, Chris Fraser, John F Dillon, Phillip Read, Ed Gane, Gregory J Dore
BACKGROUND: Despite revised guidelines that no longer exclude people who inject drugs (PWID) from treatment for hepatitis C virus (HCV) infection, many clinicians are reluctant to treat recent PWID. This study aimed to evaluate the efficacy of sofosbuvir and velpatasvir therapy in people with chronic HCV infection and recent injection drug use. METHODS: In this open-label, single-arm phase 4 trial (SIMPLIFY), we recruited participants with recent injection drug use (past 6 months) and chronic HCV genotype 1-6 infection from seven countries (19 sites)...
January 5, 2018: Lancet. Gastroenterology & Hepatology
https://www.readbyqxmd.com/read/29249202/modeling-hiv-hcv-coinfection-epidemiology-in-the-direct-acting-antiviral-era-the-road-to-elimination
#20
Victor Virlogeux, Fabien Zoulim, Pascal Pugliese, Isabelle Poizot-Martin, Marc-Antoine Valantin, Lise Cuzin, Jacques Reynes, Eric Billaud, Thomas Huleux, Firouze Bani-Sadr, David Rey, Anne Frésard, Christine Jacomet, Claudine Duvivier, Antoine Cheret, Laurent Hustache-Mathieu, Bruno Hoen, André Cabié, Laurent Cotte
BACKGROUND: HCV treatment uptake has drastically increased in HIV-HCV coinfected patients in France since direct-acting antiviral (DAA) treatment approval, resulting in HCV cure in 63% of all HIV-HCV patients by the end of 2015. We investigated the impact of scaling-up DAA on HCV prevalence in the whole HIV population and in various risk groups over the next 10 years in France using a transmission dynamic compartmental model. METHODS: The model was based on epidemiological data from the French Dat'AIDS cohort...
December 18, 2017: BMC Medicine
keyword
keyword
75058
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"